CE-Ventures, the corporate venture capital platform of Crescent Enterprises, has invested in Freya Biosciences’ $38 million Series A funding round. The trans-Atlantic biotech company focuses on women’s health, particularly microbial immunotherapies. The funding will advance the clinical development of Freya’s lead drug candidate, which targets infertility in women with dysbiotic vaginal microbiota. Additionally, the funds will support the evolution of Freya’s multi-omics data science platform, which includes microbiome sequencing and immune biomarker profiling.
CE-Ventures Partners with Freya Biosciences for $38mln Funding Boost
Latest from Blog
Arch Venture Partners secures over $3bn for Fund XIII
TLDR: Arch Venture Partners has raised over $3 billion for Fund XIII. Investors in the fund include Alaska Permanent Fund and Rockefeller Brothers Fund. In a recent development, Arch Venture Partners has
Raising Your First Venture Fund: Tips for Success
TLDR: Samir Kaji, a seasoned venture capital professional, shares a six-point plan for raising a venture fund as a first-time fund manager. Key steps include staying focused on a niche, not worrying
Exploring China’s Quantum Computing Breakthrough and VC Trends
TLDR: ONCO stock surged over 80% in pre-market after Altos Venture acquired a stake Chinese low float stocks like DUO rose over 40% in sympathy with large caps Summary: The article discusses
The Blindspot: Venture Capitalists’ Go-To Tool with Fatal Flaw
TLDR: Nader Al-Naji, founder of Bitclout, was arrested for an alleged crypto scam involving VC giant Andreessen Horowitz as a victim. VCs’ pattern matching led them to invest in Al-Naji despite red
Korean startups seek corporate investors in challenging ecosystem climate
TLDR: Korean startups are seeking corporate investors as funding becomes harder to secure. The government in South Korea has relaxed CVC rules to attract more foreign investment. Korean startups are facing a